Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain
Background Helicobacter pylori infection is associated with chronic gastritis, ulcers and gastric cancer. Antimicrobial resistance has increased worldwide affecting the efficacy of current treatments. Most guidelines recommend implementation of regional surveillance of primary antibiotic resistance...
Gespeichert in:
Veröffentlicht in: | European journal of clinical investigation 2019-08, Vol.49 (8), p.e13150-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 8 |
container_start_page | e13150 |
container_title | European journal of clinical investigation |
container_volume | 49 |
creator | Fernández‐Reyes, María Tamayo, Esther Rojas‐Rengifo, Diana Fischer, Wolfgang Carrasco‐García, Estefanía Alonso, Marta Lizasoain, Jacobo Bujanda, Luis Cosme, Ángel Montes, Milagrosa |
description | Background
Helicobacter pylori infection is associated with chronic gastritis, ulcers and gastric cancer. Antimicrobial resistance has increased worldwide affecting the efficacy of current treatments. Most guidelines recommend implementation of regional surveillance of primary antibiotic resistance of H pylori. Only a fraction of individuals infected with H pylori develop gastric diseases which are related to virulence factors of the bacteria. The aims of the study were to determine the primary antimicrobial resistance rates of H pylori and to know the virulence factors prevalence of strains circulating in Southern Europe.
Materials and Methods
Susceptibility testing by Etest to clarithromycin, levofloxacin, metronidazole, amoxicillin and tetracycline was performed in 102 isolates (99 naïve patients). The prevalence of virulence factors (cagA, vacA, oipA, babA and dupA) was evaluated in 102 H pylori isolates from patients with mild‐disease symptoms and in 22 isolates from patients with severe‐disease symptoms.
Results
Primary resistance rates were 12.1% to clarithromycin, 13.1% to levofloxacin, 24.2% to metronidazole and 0% to amoxicillin and tetracycline. Combined resistance to clarithromycin and levofloxacin was 3% and to clarithromycin and metronidazole 4%. Prevalence of virulence factors in the mild‐ and severe‐disease group was 35.3% and 81.8% for cagA, 20.6% and 54.5% for cagA/vacAs1m1, 94.1% and 95.4% for babA2, 78.4% and 100% for oipA and 30.4% and 18.2% for dupA.
Conclusions
Primary antimicrobial resistance rates were under 15% for clarithromycin and levofloxacin. The prevalence of H pylori carrying the virulent genotype cagA/vacAs1m1 was higher than 20% in the mild‐disease and 54% in the severe‐disease symptom group. |
doi_str_mv | 10.1111/eci.13150 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2250631270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2264086058</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3530-733dd604a448b3feea5bf52fc685480fcfa87ba0d7422e2e39e2c2011e6b11f13</originalsourceid><addsrcrecordid>eNp10EFLwzAUB_AgipvTg19ACl700O29pGm7o4zpBkMPKngrafrqMrq2Jh2yb2_mpgfBd8k7_PiT92fsEmGIfkakzRAFSjhifRSxDLmI-THrA2AU8nHCe-zMuRUApCj4KesJxDGPJPbZ24wqo5tc6Y5s0G6rxpqgVd2yeafaaNNtA1UXQWvNWtnd3pm10bbJjaoCS864TtWaAlMHj43tlmTr4LlVpj5nJ6WqHF0c3gF7vZ--TGbh4ulhPrlbhFpIAWEiRFHEEKkoSnNREimZl5KXOk5llEKpS5UmuYIiiTgnTmJMXHNApDhHLFEM2M0-t7XNx4Zcl62N01RVqqZm4zLOJcQCeQKeXv-hq2Zja_87r-II0hhk6tXtXvkrnbNUZofjM4RsV3fm686-6_b26pC4yddU_Mqffj0Y7cGnqWj7f1I2ncz3kV_KholA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2264086058</pqid></control><display><type>article</type><title>Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Fernández‐Reyes, María ; Tamayo, Esther ; Rojas‐Rengifo, Diana ; Fischer, Wolfgang ; Carrasco‐García, Estefanía ; Alonso, Marta ; Lizasoain, Jacobo ; Bujanda, Luis ; Cosme, Ángel ; Montes, Milagrosa</creator><creatorcontrib>Fernández‐Reyes, María ; Tamayo, Esther ; Rojas‐Rengifo, Diana ; Fischer, Wolfgang ; Carrasco‐García, Estefanía ; Alonso, Marta ; Lizasoain, Jacobo ; Bujanda, Luis ; Cosme, Ángel ; Montes, Milagrosa</creatorcontrib><description>Background
Helicobacter pylori infection is associated with chronic gastritis, ulcers and gastric cancer. Antimicrobial resistance has increased worldwide affecting the efficacy of current treatments. Most guidelines recommend implementation of regional surveillance of primary antibiotic resistance of H pylori. Only a fraction of individuals infected with H pylori develop gastric diseases which are related to virulence factors of the bacteria. The aims of the study were to determine the primary antimicrobial resistance rates of H pylori and to know the virulence factors prevalence of strains circulating in Southern Europe.
Materials and Methods
Susceptibility testing by Etest to clarithromycin, levofloxacin, metronidazole, amoxicillin and tetracycline was performed in 102 isolates (99 naïve patients). The prevalence of virulence factors (cagA, vacA, oipA, babA and dupA) was evaluated in 102 H pylori isolates from patients with mild‐disease symptoms and in 22 isolates from patients with severe‐disease symptoms.
Results
Primary resistance rates were 12.1% to clarithromycin, 13.1% to levofloxacin, 24.2% to metronidazole and 0% to amoxicillin and tetracycline. Combined resistance to clarithromycin and levofloxacin was 3% and to clarithromycin and metronidazole 4%. Prevalence of virulence factors in the mild‐ and severe‐disease group was 35.3% and 81.8% for cagA, 20.6% and 54.5% for cagA/vacAs1m1, 94.1% and 95.4% for babA2, 78.4% and 100% for oipA and 30.4% and 18.2% for dupA.
Conclusions
Primary antimicrobial resistance rates were under 15% for clarithromycin and levofloxacin. The prevalence of H pylori carrying the virulent genotype cagA/vacAs1m1 was higher than 20% in the mild‐disease and 54% in the severe‐disease symptom group.</description><identifier>ISSN: 0014-2972</identifier><identifier>EISSN: 1365-2362</identifier><identifier>DOI: 10.1111/eci.13150</identifier><identifier>PMID: 31192451</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Amoxicillin ; Anti-Bacterial Agents - pharmacology ; Antibiotic resistance ; Antibiotics ; Antiinfectives and antibacterials ; Antimicrobial agents ; Antimicrobial resistance ; Chronic infection ; Clarithromycin ; Disease resistance ; Drug resistance ; Drug Resistance, Bacterial - genetics ; Female ; Gastric cancer ; Gastritis ; Genotype ; Genotypes ; Helicobacter Infections - microbiology ; Helicobacter pylori ; Helicobacter pylori - drug effects ; Helicobacter pylori - genetics ; Helicobacter pylori - pathogenicity ; Humans ; Levofloxacin ; Male ; Metronidazole ; Middle Aged ; Pathogenicity ; Pathogens ; Phylogeography ; Signs and symptoms ; Spain ; Test procedures ; Ulcers ; Virulence ; Virulence factors ; Virulence Factors - genetics ; Young Adult</subject><ispartof>European journal of clinical investigation, 2019-08, Vol.49 (8), p.e13150-n/a</ispartof><rights>2019 Stichting European Society for Clinical Investigation Journal Foundation</rights><rights>2019 Stichting European Society for Clinical Investigation Journal Foundation.</rights><rights>Copyright © 2019 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3530-733dd604a448b3feea5bf52fc685480fcfa87ba0d7422e2e39e2c2011e6b11f13</citedby><cites>FETCH-LOGICAL-c3530-733dd604a448b3feea5bf52fc685480fcfa87ba0d7422e2e39e2c2011e6b11f13</cites><orcidid>0000-0002-2513-1109</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Feci.13150$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Feci.13150$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31192451$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernández‐Reyes, María</creatorcontrib><creatorcontrib>Tamayo, Esther</creatorcontrib><creatorcontrib>Rojas‐Rengifo, Diana</creatorcontrib><creatorcontrib>Fischer, Wolfgang</creatorcontrib><creatorcontrib>Carrasco‐García, Estefanía</creatorcontrib><creatorcontrib>Alonso, Marta</creatorcontrib><creatorcontrib>Lizasoain, Jacobo</creatorcontrib><creatorcontrib>Bujanda, Luis</creatorcontrib><creatorcontrib>Cosme, Ángel</creatorcontrib><creatorcontrib>Montes, Milagrosa</creatorcontrib><title>Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain</title><title>European journal of clinical investigation</title><addtitle>Eur J Clin Invest</addtitle><description>Background
Helicobacter pylori infection is associated with chronic gastritis, ulcers and gastric cancer. Antimicrobial resistance has increased worldwide affecting the efficacy of current treatments. Most guidelines recommend implementation of regional surveillance of primary antibiotic resistance of H pylori. Only a fraction of individuals infected with H pylori develop gastric diseases which are related to virulence factors of the bacteria. The aims of the study were to determine the primary antimicrobial resistance rates of H pylori and to know the virulence factors prevalence of strains circulating in Southern Europe.
Materials and Methods
Susceptibility testing by Etest to clarithromycin, levofloxacin, metronidazole, amoxicillin and tetracycline was performed in 102 isolates (99 naïve patients). The prevalence of virulence factors (cagA, vacA, oipA, babA and dupA) was evaluated in 102 H pylori isolates from patients with mild‐disease symptoms and in 22 isolates from patients with severe‐disease symptoms.
Results
Primary resistance rates were 12.1% to clarithromycin, 13.1% to levofloxacin, 24.2% to metronidazole and 0% to amoxicillin and tetracycline. Combined resistance to clarithromycin and levofloxacin was 3% and to clarithromycin and metronidazole 4%. Prevalence of virulence factors in the mild‐ and severe‐disease group was 35.3% and 81.8% for cagA, 20.6% and 54.5% for cagA/vacAs1m1, 94.1% and 95.4% for babA2, 78.4% and 100% for oipA and 30.4% and 18.2% for dupA.
Conclusions
Primary antimicrobial resistance rates were under 15% for clarithromycin and levofloxacin. The prevalence of H pylori carrying the virulent genotype cagA/vacAs1m1 was higher than 20% in the mild‐disease and 54% in the severe‐disease symptom group.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amoxicillin</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>Chronic infection</subject><subject>Clarithromycin</subject><subject>Disease resistance</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial - genetics</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Gastritis</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - drug effects</subject><subject>Helicobacter pylori - genetics</subject><subject>Helicobacter pylori - pathogenicity</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Male</subject><subject>Metronidazole</subject><subject>Middle Aged</subject><subject>Pathogenicity</subject><subject>Pathogens</subject><subject>Phylogeography</subject><subject>Signs and symptoms</subject><subject>Spain</subject><subject>Test procedures</subject><subject>Ulcers</subject><subject>Virulence</subject><subject>Virulence factors</subject><subject>Virulence Factors - genetics</subject><subject>Young Adult</subject><issn>0014-2972</issn><issn>1365-2362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10EFLwzAUB_AgipvTg19ACl700O29pGm7o4zpBkMPKngrafrqMrq2Jh2yb2_mpgfBd8k7_PiT92fsEmGIfkakzRAFSjhifRSxDLmI-THrA2AU8nHCe-zMuRUApCj4KesJxDGPJPbZ24wqo5tc6Y5s0G6rxpqgVd2yeafaaNNtA1UXQWvNWtnd3pm10bbJjaoCS864TtWaAlMHj43tlmTr4LlVpj5nJ6WqHF0c3gF7vZ--TGbh4ulhPrlbhFpIAWEiRFHEEKkoSnNREimZl5KXOk5llEKpS5UmuYIiiTgnTmJMXHNApDhHLFEM2M0-t7XNx4Zcl62N01RVqqZm4zLOJcQCeQKeXv-hq2Zja_87r-II0hhk6tXtXvkrnbNUZofjM4RsV3fm686-6_b26pC4yddU_Mqffj0Y7cGnqWj7f1I2ncz3kV_KholA</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Fernández‐Reyes, María</creator><creator>Tamayo, Esther</creator><creator>Rojas‐Rengifo, Diana</creator><creator>Fischer, Wolfgang</creator><creator>Carrasco‐García, Estefanía</creator><creator>Alonso, Marta</creator><creator>Lizasoain, Jacobo</creator><creator>Bujanda, Luis</creator><creator>Cosme, Ángel</creator><creator>Montes, Milagrosa</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2513-1109</orcidid></search><sort><creationdate>201908</creationdate><title>Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain</title><author>Fernández‐Reyes, María ; Tamayo, Esther ; Rojas‐Rengifo, Diana ; Fischer, Wolfgang ; Carrasco‐García, Estefanía ; Alonso, Marta ; Lizasoain, Jacobo ; Bujanda, Luis ; Cosme, Ángel ; Montes, Milagrosa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3530-733dd604a448b3feea5bf52fc685480fcfa87ba0d7422e2e39e2c2011e6b11f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amoxicillin</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>Chronic infection</topic><topic>Clarithromycin</topic><topic>Disease resistance</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial - genetics</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Gastritis</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - drug effects</topic><topic>Helicobacter pylori - genetics</topic><topic>Helicobacter pylori - pathogenicity</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Male</topic><topic>Metronidazole</topic><topic>Middle Aged</topic><topic>Pathogenicity</topic><topic>Pathogens</topic><topic>Phylogeography</topic><topic>Signs and symptoms</topic><topic>Spain</topic><topic>Test procedures</topic><topic>Ulcers</topic><topic>Virulence</topic><topic>Virulence factors</topic><topic>Virulence Factors - genetics</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández‐Reyes, María</creatorcontrib><creatorcontrib>Tamayo, Esther</creatorcontrib><creatorcontrib>Rojas‐Rengifo, Diana</creatorcontrib><creatorcontrib>Fischer, Wolfgang</creatorcontrib><creatorcontrib>Carrasco‐García, Estefanía</creatorcontrib><creatorcontrib>Alonso, Marta</creatorcontrib><creatorcontrib>Lizasoain, Jacobo</creatorcontrib><creatorcontrib>Bujanda, Luis</creatorcontrib><creatorcontrib>Cosme, Ángel</creatorcontrib><creatorcontrib>Montes, Milagrosa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández‐Reyes, María</au><au>Tamayo, Esther</au><au>Rojas‐Rengifo, Diana</au><au>Fischer, Wolfgang</au><au>Carrasco‐García, Estefanía</au><au>Alonso, Marta</au><au>Lizasoain, Jacobo</au><au>Bujanda, Luis</au><au>Cosme, Ángel</au><au>Montes, Milagrosa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain</atitle><jtitle>European journal of clinical investigation</jtitle><addtitle>Eur J Clin Invest</addtitle><date>2019-08</date><risdate>2019</risdate><volume>49</volume><issue>8</issue><spage>e13150</spage><epage>n/a</epage><pages>e13150-n/a</pages><issn>0014-2972</issn><eissn>1365-2362</eissn><abstract>Background
Helicobacter pylori infection is associated with chronic gastritis, ulcers and gastric cancer. Antimicrobial resistance has increased worldwide affecting the efficacy of current treatments. Most guidelines recommend implementation of regional surveillance of primary antibiotic resistance of H pylori. Only a fraction of individuals infected with H pylori develop gastric diseases which are related to virulence factors of the bacteria. The aims of the study were to determine the primary antimicrobial resistance rates of H pylori and to know the virulence factors prevalence of strains circulating in Southern Europe.
Materials and Methods
Susceptibility testing by Etest to clarithromycin, levofloxacin, metronidazole, amoxicillin and tetracycline was performed in 102 isolates (99 naïve patients). The prevalence of virulence factors (cagA, vacA, oipA, babA and dupA) was evaluated in 102 H pylori isolates from patients with mild‐disease symptoms and in 22 isolates from patients with severe‐disease symptoms.
Results
Primary resistance rates were 12.1% to clarithromycin, 13.1% to levofloxacin, 24.2% to metronidazole and 0% to amoxicillin and tetracycline. Combined resistance to clarithromycin and levofloxacin was 3% and to clarithromycin and metronidazole 4%. Prevalence of virulence factors in the mild‐ and severe‐disease group was 35.3% and 81.8% for cagA, 20.6% and 54.5% for cagA/vacAs1m1, 94.1% and 95.4% for babA2, 78.4% and 100% for oipA and 30.4% and 18.2% for dupA.
Conclusions
Primary antimicrobial resistance rates were under 15% for clarithromycin and levofloxacin. The prevalence of H pylori carrying the virulent genotype cagA/vacAs1m1 was higher than 20% in the mild‐disease and 54% in the severe‐disease symptom group.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>31192451</pmid><doi>10.1111/eci.13150</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2513-1109</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2972 |
ispartof | European journal of clinical investigation, 2019-08, Vol.49 (8), p.e13150-n/a |
issn | 0014-2972 1365-2362 |
language | eng |
recordid | cdi_proquest_miscellaneous_2250631270 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adult Aged Aged, 80 and over Amoxicillin Anti-Bacterial Agents - pharmacology Antibiotic resistance Antibiotics Antiinfectives and antibacterials Antimicrobial agents Antimicrobial resistance Chronic infection Clarithromycin Disease resistance Drug resistance Drug Resistance, Bacterial - genetics Female Gastric cancer Gastritis Genotype Genotypes Helicobacter Infections - microbiology Helicobacter pylori Helicobacter pylori - drug effects Helicobacter pylori - genetics Helicobacter pylori - pathogenicity Humans Levofloxacin Male Metronidazole Middle Aged Pathogenicity Pathogens Phylogeography Signs and symptoms Spain Test procedures Ulcers Virulence Virulence factors Virulence Factors - genetics Young Adult |
title | Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T05%3A26%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Helicobacter%20pylori%20pathogenicity%20and%20primary%20antimicrobial%20resistance%20in%20Northern%20Spain&rft.jtitle=European%20journal%20of%20clinical%20investigation&rft.au=Fern%C3%A1ndez%E2%80%90Reyes,%20Mar%C3%ADa&rft.date=2019-08&rft.volume=49&rft.issue=8&rft.spage=e13150&rft.epage=n/a&rft.pages=e13150-n/a&rft.issn=0014-2972&rft.eissn=1365-2362&rft_id=info:doi/10.1111/eci.13150&rft_dat=%3Cproquest_cross%3E2264086058%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2264086058&rft_id=info:pmid/31192451&rfr_iscdi=true |